At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss.
Dr. Hsia: “All of these mazdutide treatment curves did not seem to plateau, suggesting that had we continued treatment beyond 48 weeks, greater degrees of weight loss might actually have been seen.”
Participants experienced decreased HbA1c, and those on higher-dose regimens (10 and 16 mg) also experienced declines in LDL cholesterol, non-HDL cholesterol, and triglycerides.
Read the full recap from Healio: https://www.healio.com/news/endocrinology/20251118/glp1glucagon-dual-agonist-reduces-weight-across-three-dosing-regimens-in-obesity
